From CAR-T cells to protein degradation
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
Encouraging new developments in the CAR-NK niche
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
Exploring future IO-IO combination strategies and life cycle management
What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?
Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL
A look at two under the radar early developments in lymphomas which might have a shot at approval
A look at 6 IO products in the Heme space and what to watch out for.
Some intriguing new developments in DLBCL to watch out for